Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takecab

- PMLiVE

AbbVie files blockbuster hopeful elagolix for uterine fibroids

Will face competition from Myovant rival

- PMLiVE

Myovant has second phase 3 trial to back its uterine fibroids drug

Aims to take on AbbVie in new market

- PMLiVE

Takeda makes Crohn’s disease case for subcutaneous Entyvio

Hopes to aid growth

- PMLiVE

AbbVie cures STING fever with Mavupharma acquisition

Joins host of companies pursuing novel mechanism

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

- PMLiVE

AbbVie CEO Gonzalez defends Allergan takeover

Group's revenues will replace Humira loss

- PMLiVE

AbbVie to acquire Allergan for $63bn

Deal based on major cuts and diversified portfolio

- PMLiVE

AbbVie’s upadacitinib tops Humira again in arthritis trial

Firm says pipeline drug only JAK inhibitor to show superiority

- PMLiVE

Setback for Takeda as Ninlaro flunks amyloidosis trial

Curbs expansion plans for myeloma drug

- PMLiVE

European approval for Skyrizi, hot on the heels of US

Welcome news, but can't replace $20bn Humira

- PMLiVE

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links